Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Apr 23, 2026
Reporting period
Not applicable
Filed with the SEC
Apr 27, 2026
DirectorGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001225208-26-004651
Filed / recorded
Apr 27, 2026, 10:22 PM UTC
Added to OQRO
Oct 1, 2026, 11:17 PM UTC
Parser
form4-xml-v1
Data quality
Verified: identifiers matched exactly
Issuer
PFIZER INC
Issuer CIK
78003
Ticker
PFE
Reporting person
James C Smith
Relationship
Director
Security
Phantom Stock Units
Table
Derivative (Table II)
Transaction date
Apr 23, 2026
Transaction code
A
Shares / units
7,686.539
Price per share
$26.67
Acquired / disposed
Acquired (A)
Shares owned after
178,111.302
Ownership form
Direct
Amendment
No
Footnotes from the filing
Each unit represents one phantom share of common stock.
Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors.
The Department of Defense placed a delivery order for $2.2K of Pfizer's CYKLOKAPRON on May 20, 2026. This is a routine purchase under an existing contract open to all bidders, part of $652K in similar awards over the past year.
